Showing 2431-2440 of 10490 results for "".
Updates on Psoriasis Biologics
https://reachmd.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeHow Early Experience With PDT Can Provide Career Pathways
https://practicaldermatology.com/series/pdt-in-practice/how-early-experience-with-pdt-can-provide-career-pathways/20212/Adam Friedman, MD, professor and chair of dermatology at George Washington University, discusses how early-career experience with photodynamic therapy, including exposure to doctor-mentors in the field, gave him professional skills and connections that prepared him for later-career opportunities.Landing in Dermatology
https://practicaldermatology.com/series/scientifically-speaking/landing-in-dermatology/20129/Humberto Antunes talks to host Joel L. Cohen, MD about how he got his start in dermatology and why the field appealed to him.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eEye Opener
https://practicaldermatology.com/programs/practical-dermatology/eye-opener/19918/From each individual's implicit bias to the systemic bias that influences the tools of research and clinical practice, innumerable factors go into every patient encounter. Only individuals who are open to recognizing and confronting bias can overcome it. Panelists share their personal perspectives oPatient Assessment: A Key to AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/patient-assessment-a-key-to-ad-care/19889/What is the Quality of Care in Atopic Dermatitis initiative, and why is it important? Dr. Stephan Weidinger shares his thoughts on the importance of this "impressive" program and offers suggestions to improve the assessment and care of patents with eczema.DERM2020 Content Recap: Kara Gooding, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-kara-gooding-pa-c/19841/DERM2020 Faculty Kara Gooding, PA-C talks a bit about the case she presented at DERM2020.COVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aInjectable Beauty: New Uses for Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/injectable-beauty-new-uses-for-dermal-fillers/19766/Today fillers are being used to do more than just chase wrinkles and folds, shares Jeanette Black, MD. Some exciting new uses include biostimulation with Sculptra or hyperdilute Radiesse to addresscellulite and skin laxity along with the use of intradermal hyaluronic acid-based fillers for skin hydr